Michael Michael

The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (F-18) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors

Mei Sim Lung, Rodney J Hicks, Nick Pavlakis, Emma Link, Michael Jefford, Benjamin Thomson, David K Wyld, Winston Liauw, Timothy Akhurst, Narmatha Kuru, Michael Michael

Journal article  |  2020  |  Asia-Pacific Journal of Clinical Oncology

AIMS: This multicenter phase II trial evaluates the efficacy of everolimus in poor prognosis grade 2 (G2) pancreatic neuroendocrin..

Prognostic factors influencing survival in patients undergoing cytoreductive surgery with HIPEC for isolated colorectal peritoneal metastases: A systematic review and meta-analysis.

Vignesh Narasimhan, Sabrina Tan, Joseph Kong, Toan Pham, Michael Michael, Robert Ramsay, Satish Warrier, Alexander Heriot

Journal article  |  2020  |  Colorectal Disease

BACKGROUND AND AIMS: Peritoneal metastases from colorectal cancer confer the worst survival among all sites of metastases. The ado..

Re-do cytoreductive surgery for peritoneal surface malignancy: Is it worthwhile?

Vignesh Narasimhan, Francis Cheung, Peadar Waters, Oliver Peacock, Satish Warrier, Craig Lynch, Michael Michael, Robert Ramsay, Alexander Heriot

Journal article  |  2019  |  The Surgeon

BACKGROUND AND OBJECTIVES: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers selected pati..

First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).

Toan Pham, Lloyd Pereira, Sara Roth, Laura Galletta, Emma Link, Tim Akhurst, Ben Solomon, Michael Michael, Phillip Darcy, Shienny Sampurno, Alexander Heriot, Robert Ramsay, Jayesh Desai

Journal article  |  2019  |  Contemporary Clinical Trials Communications

Background: MYB is a transcription factor that is overexpressed in colorectal cancer (CRC) and also a driver mutation in adenoid c..

Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention

Lisa Guccione, Karla Gough, Allison Drosdowsky, Krista Fisher, Timothy Price, Nick Pavlakis, Mustafa Khasraw, David Wyld, David Ransom, Grace Kong, Megan Rogers, Simone Leyden, John Leyden, Michael Michael, Penelope Schofield

Journal article  |  2019  |  JMIR Research Protocols

Perceptions in the management of colorectal peritoneal metastases: A bi-national survey of colorectal surgeons

Vignesh Narasimhan, Satish Warrier, Michael Michael, Jacob J McCormick, Robert Ramsay, Craig Lynch, Alexander Heriot

Journal article  |  2019  |  Pleura and Peritoneum

Background: There is great variability in the uptake of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy..

Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.

Vignesh Narasimhan, Satish Warrier, Michael Michael, Robert Ramsay, Alexander Heriot

Journal article  |  2019  |  Journal of Gastrointestinal Surgery

BACKGROUND AND OBJECTIVES: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can offer selected p..

The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma

Grace Kong, Tess Schenberg, Christopher J Yates, Alison Trainer, Nirupa Sachithanandan, Amir Iravani, Aravind Ravi Kumar, Michael S Hofman, Tim Akhurst, Michael Michael, Rodney J Hicks

Journal article  |  2019  |  The Journal of Clinical Endocrinology & Metabolism

Purpose: Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and requ..

Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience

Vignesh Narasimhan, Maneka Britto, Pham Toan, Satish Warrier, Arun Naik, A Craig Lynch, Michael Michael, Jeanne Tie, Robert Ramsay, Alexander Heriot

Journal article  |  2019  |  Diseases of the Colon & Rectum

BACKGROUND: Colorectal cancer is the second leading cause of cancer-related mortality worldwide. Peritoneal metastases carry the w..

Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care

Braden Woodhouse, Sharon Pattison, Eva Segelov, Simron Singh, Kate Parker, Grace Kong, William Macdonald, David Wyld, Goswin Meyer-Rochow, Nick Pavlakis, Siobhan Conroy, Vallerie Gordon, Jonathan Koea, Nicole Kramer, Michael Michael, Kate Wakelin, Tehmina Asif, Dorothy Lo, Timothy Price, Ben Lawrence, et al.

Journal article  |  2019  |  Journal of Clinical Medicine

Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms

Vignesh Narasimhan, Pham Toan, Satish Warrier, A Craig Lynch, Michael Michael, Jeanne Tie, Robert Ramsay, Alexander Heriot

Journal article  |  2019  |  ANZ Journal of Surgery

BACKGROUND: Appendiceal epithelial neoplasms are rare cancers. Management of peritoneal disease from appendiceal neoplasms has his..

The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancers

Ashika D Maharaj, Jennifer F Holland, Ri O Scarborough, Sue M Evans, Liane J Ioannou, Wendy Brown, Daniel G Croagh, Charles HC Pilgrim, James G Kench, Lara R Lipton, Trevor Leong, John J McNeil, Mehrdad Nikfarjam, Ahmad Aly, Paul R Burton, Paul A Cashin, Julie Chu, Cuong P Duong, Peter Evans, David Goldstein, et al.

Journal article  |  2019  |  BMJ Open

PURPOSE: The Upper Gastrointestinal Cancer Registry (UGICR) was developed to monitor and improve the quality of care provided to p..

Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases

Vignesh Narasimhan, Atandrila Das, Satish Warrier, Craig Lynch, Jacob McCormick, Jeanne Tie, Michael Michael, Robert Ramsay, Alexander Heriot

Journal article  |  2019  |  Langenbeck's Archives of Surgery

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series

Isaac Goncalves, Kate Burbury, Michael Michael, Amir Iravani, Aravind S Ravi Kumar, Tim Akhurst, Ing S Tiong, Piers Blombery, Michael S Hofman, David Westerman, Rodney J Hicks, Grace Kong

Journal article  |  2019  |  European Journal of Nuclear Medicine and Molecular Imaging

Colorectal peritoneal metastases: Exploring the immune landscape and the potential of immunotherapy using organoid models

Vignesh Narasimhan, Pham Toan, Kasmira Wilson, Susan Woods, Daniel Worthley, Jeanne Tie, Michael Michael, Alexander Heriot, Robert Ramsay

Conference Proceedings  |  2019  |  Immunology

Early Outcomes of Surgery for Carcinoid Heart Disease.

Matthew S Yong, Grace Kong, Prakash Ludhani, Michael Michael, John Morgan, Michael S Hofman, Rodney J Hicks, Marco Larobina

Journal article  |  2019  |  Heart, Lung and Circulation

BACKGROUND: The prognosis of patients with metastatic neuroendocrine neoplasms (NEN) continues to improve with modern oncological ..

Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.

Michael Michael, Rachel Wong, Sanjeev Singh Gill, David Goldstein, Sam Ngan, Alexander Graham Heriot, Emma Link, Maria Farrell, Paul J Neeson, Robert George Ramsay, Kasmira Wilson, Catherine Mitchell, Jeanne Tie, Nick Pavlakis, John Raymond Zalcberg, Eva Segelov

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

A phase II clinical trial of ipilimumab/nivolumab combination immunotherapy in patients with rare upper gastrointestinal, neuroendocrine, and gynecological malignancies.

Oliver Klein, Damien Kee, Ben Markman, Rachael Chang Lee, Michael Michael, Linda R Mileshkin, Clare L Scott, Richelle Linklater, Sid Menon, Niall C Tebbutt, Jodie Palmer, Andreas Behren, Jonathan S Cebon

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.

Vignesh Narasimhan, Kasmira Wilson, Maneka Britto, Satish Warrier, A Craig Lynch, Michael Michael, Jeanne Tie, Tim Akhurst, Catherine Mitchell, Robert Ramsay, Alexander Heriot

Journal article  |  2019  |  Journal of Gastrointestinal Surgery

BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare clinical presentation, with considerable morbidity and mortality if left untrea..

Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)

Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, Tim Akhurst, Amichay Meirovitz, Ofra Maimon, Yodphat Krausz, Jeremy Godefroy, Michael Michael, David J Gross, Rodney J Hicks

Journal article  |  2019  |  European Journal of Nuclear Medicine and Molecular Imaging

A clinical trial with protracted infusion 5-fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus

David Ngan, Julie Chu, Sarat Chander, Michael Michael, Alexander G Heriot, Samuel Y Ngan, Danny Rischin, Trevor Leong

Journal article  |  2019  |  Asia-Pacific Journal of Clinical Oncology

Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series

I Goncalves, K Burbury, D Westerman, P Blombery, IS Tiong, A Iravani, A Ravikumar, M Michael, M Hofman, T Akhurst, R Hicks, G Kong

Conference Proceedings  |  2019  |  NEUROENDOCRINOLOGY

CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience

Arvind Sahu, Michael Jefford, Julia Lai-Kwon, Alesha Thai, Rodney J Hicks, Michael Michael

Journal article  |  2019  |  Journal of Oncology

Investigating Nutrition-Related Complications and Quality of Life in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Protocol for a Mixed-Methods Prospective Study

Erin Laing, Nicole Kiss, Michael Michael, Karla Gough, Meinir Krishnasamy

Journal article  |  2018  |  JMIR Research Protocols

Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Joseph Cherng Huei Kong, Glen Robert Guerra, Rosemary Magdalena Millen, Sara Roth, Huiling Xu, Paul Joseph Neeson, Phillip Kevin Darcy, Michael Henry Kershaw, Shienny Sampurno, Jordane Malaterre, David Shi Hao Liu, Duc Pham Toan, Vignesh Narasimhan, Minyu Wang, Yu-Kuan Huang, Kumar Visvanathan, Jacob McCormick, Andrew Craig Lynch, Satish Warrier, Michael Michael, et al.

Journal article  |  2018  |  JCO Precision Oncology

Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood

Z Liu, J Martin, L Orme, B Seddon, J Desai, W Nicholls, D Thomson, D Porter, G McCowage, C Underhill, N Cranswick, M Michael, M Zacharin, A Herschtal, J Sivasuthan, DM Thomas

Journal article  |  2018  |  Cancer Chemotherapy and Pharmacology

Optical barcoding highlights novel characteristics of treatment resistant cells in metastatic colorectal cancer

Frederic Hollande, Corina Behrenbruch, Carolyn Shembrey, Pu Xue Qiao, Davide Ferrari, Benjamin Thomson, Michael Michael, Alexander Heriot

Conference Proceedings  |  2018  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Capecitabine and temozolomide (CAPTEM) for intermediate to high grade metastatic neuroendocrine tumours (NET): A single centre experience

Arvind Sahu, Michael Jefford, Julia Lai-Kwon, Rod Hicks, Alesha Thai, Michael Michael

Conference Proceedings  |  2018  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Nutritional impact of a gastroenteropancreatic neuroendocrine tumour from a patient's perspective

Erin Laing, Nicole Kiss, Michael Michael, Mei Krishnasamy

Conference Proceedings  |  2018  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors

Simron Singh, Lesley Moody, David L Chan, David C Metz, Jonathan Strosberg, Timothy Asmis, Dale L Bailey, Emily Bergsland, Kari Brendtro, Richard Carroll, Sean Cleary, Michelle Kim, Grace Kong, Calvin Law, Ben Lawrence, Alexander McEwan, Caitlin McGregor, Michael Michael, Janice Pasieka, Nick Pavlakis, et al.

Journal article  |  2018  |  JAMA Oncology

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM (TM) system in a quaternary oncology centre

Michael Moloney, David Faulkner, Emma Link, Danny Rischin, Ben Solomon, Annette M Lim, John R Zalcberg, Michael Jefford, Michael Michael

Journal article  |  2018  |  Cancer Chemotherapy and Pharmacology

Potential issues with complementary medicines commonly used in the cancer population: A retrospective review of a tertiary cancer center's experience

Sally L Brooks, Gail Rowan, Michael Michael

Journal article  |  2018  |  Asia-Pacific Journal of Clinical Oncology

Induction PRRT With CAPTEM Chemotherapy in a High-risk Population of Metastatic Neuroendocrine Neoplasia (NEN): Balancing Efficacy With Risk

AS Ravi Kumar, J Ferdinandus, J Callahan, T Akhurst, MS Hofman, A Iravani, G Kong, M Michael, RJ Hicks

Conference Proceedings  |  2018  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis

JC Kong, GR Guerra, SK Warrier, A Craig Lynch, M Michael, SY Ngan, W Phillips, G Ramsay, AG Heriot

Journal article  |  2018  |  Colorectal Disease

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey

John Leyden, Nick Pavlakis, David Chan, Michael Michael, Stephen Clarke, Mustafa Khasraw, Timothy Price

Journal article  |  2018  |  Asia-Pacific Journal of Clinical Oncology

Capecitabine and temozolomide (CAPTEM) for intermediate to high grade metastatic neuroendocrine tumours (NET): A single centre experience.

Arvind Sahu, Michael Jefford, Rodney J Hicks, Michael Michael

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Surgical stress response and promotion of metastasis in colorectal cancer: a complex and heterogeneous process

Corina Behrenbruch, Carolyn Shembrey, Sophie Paquet-Fifield, Christina Molck, Hyun-Jung Cho, Michael Michael, Benjamin NJ Thomson, Alexander G Heriot, Frederic Hollande

Journal article  |  2018  |  Clinical & Experimental Metastasis

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis

Sue Ping Thang, Mei Sim Lung, Grace Kong, Michael S Hofman, Jason Callahan, Michael Michael, Rodney J Hicks

Journal article  |  2018  |  European Journal of Nuclear Medicine and Molecular Imaging

AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.

Lorraine A Chantrill, Lara Rachel Lipton, Michael Hofman, Val Gebski, Anthony Gill, Ben Markman, Sonia Yip, Christos Stelios Karapetis, Nick Pavlakis, Shu Fen Wong, David Turner Ransom, Katrin Marie Sjoquist, Adnan Nagrial, Michael Michael, Uzma Rayani, Martinus Oostendorp, John Simes, Mustafa Khasraw

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Exploring Nutrition Screening and Management Practices amongst Health Professionals Managing Patients with Neuroendocrine Tumors

E Kennedy, N Kiss, M Michael, K Gough, A Drosdowsky, M Krishnasamy

Conference Proceedings  |  2018  |  NEUROENDOCRINOLOGY

Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study

E Kennedy, N Kiss, M Michael, K Gough, A Drosdowsky, M Krishnasamy

Conference Proceedings  |  2018  |  NEUROENDOCRINOLOGY

Bridging Bio-Nano Science and Cancer Nanomedicine

Mattias Bjornmalm, Kristofer J Thurecht, Michael Michael, Andrew M Scott, Frank Caruso

Journal article  |  2017  |  ACS Nano

Treatment of peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy in colorectal cancer

Corina Behrenbruch, Frederic Hollande, Benjamin Thomson, Michael Michael, Satish K Warrier, Craig Lynch, Alexander Heriot

Journal article  |  2017  |  ANZ Journal of Surgery

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG

Trevor Leong, B Mark Smithers, Karin Haustermans, Michael Michael, Val Gebski, Danielle Miller, John Zalcberg, Alex Boussioutas, Michael Findlay, Rachel L O'Connell, Jaclyn Verghis, David Willis, Tomas Kron, Melissa Crain, William K Murray, Florian Lordick, Carol Swallow, Gail Darling, John Simes, Rebecca Wong

Journal article  |  2017  |  Annals of Surgical Oncology

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Michael Michael, Yung-Jue Bang, Young Suk Park, Yoon-Koo Kang, Tae Min Kim, Oday Hamid, Donald Thornton, Sonya C Tate, Eyas Raddad, Jeanne Tie

Journal article  |  2017  |  Targeted Oncology

Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases.

J Zhao, KMC van Mierlo, J Gómez-Ramírez, H Kim, CHC Pilgrim, P Pessaux, SS Rensen, EP van der Stok, FG Schaap, O Soubrane, T Takamoto, L Viganò, B Winkens, CHC Dejong, SWM Olde Damink, undefined Chemotherapy-Associated Liver Injury (CALI) consortium

Journal article  |  2017  |  British Journal of Surgery

BACKGROUND: The impact of chemotherapy-associated liver injury (CALI) on postoperative outcome in patients undergoing partial hepa..

Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study

Brian G Czito, Dustin A Deming, Gayle S Jameson, Mary F Mulcahy, Houman Vaghefi, Matthew W Dudley, Kyle D Holen, Angela DeLuca, Rajendar K Mittapalli, Wijith Munasinghe, Lei He, John R Zalcberg, Samuel Y Ngan, Philip Komarnitsky, Michael Michael

Journal article  |  2017  |  The Lancet Gastroenterology & Hepatology

Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).

Mei Sim Lung, Michael Hofman, Grace Kong, Sue-Ping Thang, Michael Michael, Rodney J Hicks

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

The utility of genomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynannics: The PREDICT IR study.

Michael Michael, Winston Liauw, Sue-Anne McLachlan, Emma Link, Anetta Matera, Mick Thompson, Michael Jefford, Rodney J Hicks, Carleen Cullinane, Ian Campbell, Philip James Beale, Christos Stelios Karapetis, Timothy Price, Matthew E Burge

Conference Proceedings  |  2017  |  Journal of Clinical Oncology

Lu-177-Dotatate for Midgut Neuroendocrine Tumors

Michael S Hofman, Michael Michael, Rodney J Hicks

Journal article  |  2017  |  New England Journal of Medicine

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review

Michael Michael, Rocio Garcia-Carbonero, Matthias M Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J Hicks

Journal article  |  2017  |  The Oncologist

High clinical and morphologic response using Y-90-DOTA-octreotate sequenced with Lu-177-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours

Grace Kong, Jason Callahan, Michael S Hofman, David A Pattison, Tim Akhurst, Michael Michael, Peter Eu, Rodney J Hicks

Journal article  |  2017  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases

T Bird, M Michael, M Bressel, J Chu, S Chander, P Cooray, J McKendrick, M Jefford, A Heriot, M Steel, T Leong, S Ngan

Journal article  |  2017  |  Acta Oncologica

Neoadjuvant (90)Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report

Jennifer Ryan, Timothy Akhurst, A Craig Lynch, Michael Michael, Alexander G Heriot

Journal article  |  2017  |  ANZ Journal of Surgery

Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy

Mustafa Khasraw, Sumitra Ananda, Michael Michael

Journal article  |  2016  |  Expert Review of Anticancer Therapy

Relative Value of Restaging MRI, CT, and FDG-PET Scan After Preoperative Chemoradiation for Rectal Cancer

Daniel A Schneider, Timothy J Akhurst, Samuel Y Ngan, Satish K Warrier, Michael Michael, Andrew C Lynch, Luc Te Marvelde, Alexander G Heriot

Journal article  |  2016  |  Diseases of the Colon & Rectum

Colorectal cancer

Alex Boussioutas, Stephen Fox, Iris Nagtegaal, Alexander Heriot, Jonathan Knowles, Michael Michael, Sam Ngan, Kathryn Field, John Zalcberg

Book Chapter  |  2016

This chapter covers colorectal cancer, and includes information on epidemiology, risk factors (chronic inflammation/inflammatory b..

Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention

Maria-Pia Bernardi, Samuel Y Ngan, Michael Michael, A Craig Lynch, Alexander G Heriot, Robert G Ramsay, Wayne A Phillips

Journal article  |  2015  |  The Lancet Oncology

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer

Kiley WJ Loh, Michael Michael, John R Zalcberg, Michael Jefford

Journal article  |  2015  |  Clinical Colorectal Cancer

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)

Trevor Leong, B Mark Smithers, Michael Michael, Val Gebski, Alex Boussioutas, Danielle Miller, John Simes, John Zalcberg, Karin Haustermans, Florian Lordick, Christoph Schuhmacher, Carol Swallow, Gail Darling, Rebecca Wong

Journal article  |  2015  |  BMC Cancer

Modifying the Poor Prognosis Associated with F-18-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT)

Michael S Hofman, Michael Michael, Raghava Kashyap, Rodney J Hicks

Journal article  |  2015  |  Journal of Nuclear Medicine

Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC

Michael Michael, Shane C White, Ehtesham Abdi, Louise Nott, Phillip Clingan, Allan Zimet, Peter Button, Daniel Gregory, Benjamin Solomon, Alexander Dobrovic, Hongdo Do, Stephen Clarke

Journal article  |  2015  |  Asia-Pacific Journal of Clinical Oncology

Favourable outcomes of Lu-177-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours

Raghava Kashyap, Michael S Hofman, Michael Michael, Grace Kong, Timothy Akhurst, Peter Eu, Diana Zannino, Rodney J Hicks

Journal article  |  2015  |  European Journal of Nuclear Medicine and Molecular Imaging

An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer

Yeh Chen Lee, Michael Michael, John R Zalcberg

Journal article  |  2015  |  Expert Opinion on Investigational Drugs

Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer

M Michael, S Chander, J McKendrick, JR MacKay, M Steel, R Hicks, A Heriot, T Leong, P Cooray, M Jefford, J Zalcberg, M Bressel, B McClure, SY Ngan

Journal article  |  2014  |  British Journal of Cancer

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

G Kong, M Thompson, M Collins, A Herschtal, MS Hofman, V Johnston, P Eu, M Michael, Rodney J Hicks

Journal article  |  2014  |  European Journal of Nuclear Medicine and Molecular Imaging

Systematic Review of FDG-PET Prediction of Complete Pathological Response and Survival in Rectal Cancer

Sameer Memon, A Craig Lynch, Timothy Akhurst, Samuel Y Ngan, Satish K Warrier, Michael Michael, Alexander G Heriot

Journal article  |  2014  |  Annals of Surgical Oncology

Impact of advancing age on treatment and outcomes in anal cancer

Marcus Foo, Emma Link, Trevor Leong, Julie Chu, Mark T Lee, Sarat Chander, Phillip K Tran, Jonathan M Tomaszewski, Michael Michael, Alexander Heriot, Samuel Y Ngan

Journal article  |  2014  |  Acta Oncologica

Adjuvant therapy for colorectal cancer

M Michael, JR Zalcberg

Journal article  |  2014  |  Cancer Forum

Understanding how cancer patients actualise, relinquish, and reject advance care planning: implications for practice

Natasha Michael, Clare O'Callaghan, Josephine Clayton, Annabel Pollard, Nikola Stepanov, Odette Spruyt, Michael Michael, David Ball

Journal article  |  2013  |  Supportive Care in Cancer

A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer

M Michael, J Zalcberg, P Gibbs, L Lipton, M Gouillou, M Jefford, G McArthur, M Copeman, K Lynch, NC Tebbutt

Journal article  |  2013  |  Cancer Chemotherapy and Pharmacology

Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors

Stephen J Clarke, Christos S Karapetis, Peter Gibbs, Nick Pavlakis, Jayesh Desai, Michael Michael, Niall C Tebbutt, Tim J Price, Josep Tabernero

Journal article  |  2013  |  Critical Reviews in Oncology Hematology

Individualisation of the systemic biologic therapy for advanced colorectal cancer: Light beyond K-ras status

S Ananda, M Michael

Book Chapter  |  2012  |  International Journal of Cancer Prevention

Metastatic colorectal cancer (CRC) is one of the most common malignancies in the Western world. The number of active anti-cancer a..

Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme

JD Mellor, P Van Koeverden, SWK Yip, A Thakerar, SW Kirsa, M Michael

Journal article  |  2012  |  Internal Medicine Journal

Hypoxic enhancement of exosome release by breast cancer cells.

Hamish W King, Michael Z Michael, Jonathan M Gleadle

Journal article  |  2012  |  BMC Cancer

BACKGROUND: Exosomes are nanovesicles secreted by tumour cells which have roles in paracrine signalling during tumour progression,..

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

M Michael, N Pavlakis, P Clingan, R De Boer, M Johnston, S Clarke

Journal article  |  2012  |  Oncology Reports

Twenty-Five-Year Experience With Radical Chemoradiation for Anal Cancer

Jonathan M Tomaszewski, Emma Link, Trevor Leong, Alexander Heriot, Melisa Vazquez, Sarat Chander, Julie Chu, Marcus Foo, Mark T Lee, Craig A Lynch, John Mackay, Michael Michael, Phillip Tran, Samuel Y Ngan

Journal article  |  2012  |  International Journal of Radiation: Oncology - Biology - Physics

Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidity

Charles HC Pilgrim, Laveniya Satgunaseelan, Alan Pham, William Murray, Emma Link, Marty Smith, Val Usatoff, Peter M Evans, Simon Banting, Benjamin N Thomson, Wayne A Phillips, Michael Michael

Journal article  |  2012  |  HPB: the official journal of the IHPBA

Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C-14-erythromycin breath test and the antipyrine clearance test

M Michael, C Cullinane, A Hatzimihalis, C O'Kane, A Milner, R Booth, S Schlicht, SJ Clarke, P Francis

Journal article  |  2012  |  Cancer Chemotherapy and Pharmacology

Medical Therapy of Pancreatic Cancer: Current Status and Future Targets

E Livshin, M Michael

Book Chapter  |  2012

How to Treat Neuroendocrine Tumours

MS Hofman, M Michael, BN Thomson, RJ Hicks

Journal article  |  2012  |  Australian Doctor

Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?

Linda Mileshkin, Bhaumik Shah, Michael Michael

Journal article  |  2012  |  Chemotherapy Research and Practice

There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of personalize..

The developing clinical problem of chemotherapy-induced hepatic injury

Charles HC Pilgrim, Benjamin N Thomson, Simon Banting, Wayne A Phillips, Michael Michael

Journal article  |  2012  |  ANZ Journal of Surgery

MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, Michael Michael, Stephen B Fox, Kristin Bergethon, Gregory Y Lauwers, James G Christensen, Keith D Wilner, Daniel A Haber, Ravi Salgia, Yung-Jue Bang, Jeffrey W Clark, Benjamin J Solomon, A John Iafrate

Journal article  |  2011  |  Journal of Clinical Oncology

A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative Therapy Trans Tasman Radiation Oncology Study TROG 03.07

Bryan H Burmeister, Michael Michael, Elizabeth Burmeister, Sharon Cox, Margot Lehman, Andrew Wirth, Keith Horwood, Giuseppe Sasso, Barham Forouzesh, David Ball

Journal article  |  2011  |  Journal of Thoracic Oncology

FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy

FL Day, E Link, S Ngan, T Leong, K Moodie, C Lynch, M Michael, E de Winton, A Hogg, RJ Hicks, A Heriot

Journal article  |  2011  |  British Journal of Cancer

Metabolic Response of Rectal Cancer Assessed by 18-FDG PET Following Chemoradiotherapy is Prognostic for Patient Outcome

JMC Yeung, V Kalff, RJ Hicks, E Drummond, E Link, Y Taouk, M Michael, S Ngan, AC Lynch, AG Heriot

Journal article  |  2011  |  Diseases of the Colon and Rectum

Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research

Shorn Goel, Jacquie Chirgwin, Prudence Francis, Robin Stuart-Harris, Joanna Dewar, Linda Mileshkin, Ray Snyder, Michael Michael, Bogda Koczwara

Journal article  |  2011  |  The Breast Journal

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes

Madhu S Singh, Prudence A Francis, Michael Michael

Journal article  |  2011  |  The Breast Journal

ADJUVANT CHEMORADIATION FOR GASTRIC CANCER USING EPIRUBICIN, CISPLATIN, AND 5-FLUOROURACIL BEFORE AND AFTER THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY WITH CONCURRENT INFUSIONAL 5-FLUOROURACIL: A MULTICENTER STUDY OF THE TRANS-TASMAN RADIATION ONCOLOGY GROUP

Trevor Leong, Daryl Lim Joon, David Willis, Jayasingham Jayamoham, Nigel Spry, Jennifer Harvey, Juliana Di Iulio, Alvin Milner, G Bruce Mann, Michael Michael

Journal article  |  2011  |  International Journal of Radiation: Oncology - Biology - Physics

miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus.

Cameron M Smith, David I Watson, Mary P Leong, George C Mayne, Michael Z Michael, Bas PL Wijnhoven, Damian J Hussey

Journal article  |  2011  |  World Journal of Gastroenterology

AIM: To investigate miR-200 family expression in Barrett's epithelium, gastric and duodenal epithelia, and esophageal adenocarcino..

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer

FL Day, T Leong, S Ngan, R Thomas, M Jefford, JR Zalcberg, D Rischin, J McKendick, AD Milner, J Di Iulio, A Matera, M Michael

Journal article  |  2011  |  British Journal of Cancer

Targeted Therapies for Gastric Cancer Current Status

Jaclyn Yoong, Michael Michael, Trevor Leong

Journal article  |  2011  |  Drugs

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.

M Michael, G Vlahovic, K Khamly, KJ Pierce, F Guo, AJ Olszanski

Journal article  |  2010  |  British Journal of Cancer

BACKGROUND: Tumoural interstitial hypertension, possibly modulated by platelet-derived and vascular endothelial growth factor rece..

Lu-177-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity In-111-octreotide

Daniel Hubble, Grace Kong, Michael Michael, Val Johnson, Shakher Ramdave, Rodney John Hicks

Journal article  |  2010  |  European Journal of Nuclear Medicine and Molecular Imaging

The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy.

Christine Carrington, Leanne Stone, Bogda Koczwara, Christina Searle, Jim Siderov, Ben Stevenson, Michael Michael, Susan Hyde, Angela Booth, Shelley Rushton, undefined Clinical Oncological Society of Australia

Journal article  |  2010  |  Asia-Pacific Journal of Clinical Oncology

The issue of medication safety is highly significant when anti-cancer therapy is used as a treatment modality due to the high pote..

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer

NM Corcoran, CM Hovens, M Michael, MA Rosenthal, AJ Costello

Journal article  |  2010  |  British Journal of Cancer

Antitumor Effect of Somatostatin Analogs in Neuroendocrine Tumors

Yu Jo Chua, Michael Michael, John R Zalcberg, Rod J Hicks, David Goldstein, Winston Liauw, Timothy Price

Journal article  |  2010  |  Journal of Clinical Oncology

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

E Van Cutsem, F Rivera, S Berry, A Kretzschmar, M Michael, M DiBartolomeo, M-A Mazier, J-L Canon, V Georgoulias, M Peeters, J Bridgewater, D Cunningham, undefined First BEAT investigators

Journal article  |  2009  |  Annals of Oncology

BACKGROUND: Bevacizumab significantly improves survival when added to chemotherapy for metastatic colorectal cancer (mCRC). The Be..

Pancreatic cancer: Advances in medical therapy

A Weckhardt, M Michael

Journal article  |  2009  |  Expert Review of Clinical Pharmacology

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

W Chua, D Goldstein, CK Lee, H Dhillon, M Michael, P Mitchell, SJ Clarke, B Iacopetta

Journal article  |  2009  |  British Journal of Cancer

LOCAL CONTROL AND SURVIVAL FOLLOWING CONCOMITANT CHEMORADIOTHERAPY IN INOPERABLE STAGE I NON-SMALL-CELL LUNG CANCER

Marie-Pierre Campeau, Alan Herschtal, Greg Wheeler, Michael Mac Manus, Andrew Wirth, Michael Michael, Annette Hogg, Elizabeth Drummond, David Ball

Journal article  |  2009  |  International Journal of Radiation Oncology*Biology*Physics

Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation.

Daniel L Worthley, Andrew Ruszkiewicz, Ruth Davies, Sarah Moore, Ian Nivison-Smith, L Bik To, Peter Browett, Robyn Western, Simon Durrant, Jason So, Graeme P Young, Charles G Mullighan, Peter G Bardy, Michael Z Michael

Journal article  |  2009  |  Stem Cells

This study characterized the contribution of bone marrow-derived cells to human neoplasia and the perineoplastic stroma. The Austr..

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

Michael Michael, Peter Gibbs, Robert Smith, Alex Godwood, Stuart Oliver, Niall Tebbutt

Journal article  |  2009  |  Investigational New Drugs

The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum

Jennifer A Westwood, William K Murray, Melanie Trivett, Nicole M Haynes, Benjamin Solomon, Linda Mileshkin, David Ball, Michael Michael, Angela Burman, Preethi Mayura-Guru, Joseph A Trapani, Stefan Peinert, Dirk Honemann, H Miles Prince, Andrew M Scott, Mark J Smyth, Phillip K Darcy, Michael H Kershaw

Journal article  |  2009  |  Journal of Immunotherapy

A phase I trial of Capecitabine plus Gemcitabine with radical radiation for locally advanced pancreatic cancer

M Michael, T Price, SY Ngan, V Ganju, AH Strickland, A Muller, K Khamly, AD Milner, J Dilulio, A Matera, JR Zalcberg, T Leong

Journal article  |  2009  |  British Journal of Cancer

A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients

Peter Gibbs, Tracey J Brown, Raymond Ng, Ross Jennens, Edith Cinc, Minh Pho, Michael Michael, Richard M Fox

Journal article  |  2009  |  Chemotherapy

Role of xenobiotic metabolic enzymes in cancer epidemiology.

Madhu S Singh, Michael Michael

Book  |  2009  |  Methods in Molecular Biology

The cause of the majority of cancers is poorly understood albeit multifactorial. The ultimate consequence of etiological factors w..

Part II: Liver function in oncology: towards safer chemotherapy use.

Kathryn M Field, Michael Michael

Journal article  |  2008  |  The Lancet Oncology

The liver is fundamentally important in drug metabolism. In oncology, the astute clinician must not only understand the meaning an..

Long-term survival following chemoradiation for inoperable non-small cell lung cancer

Nikki M Plumridge, Michael J Millward, Danny Rischin, Michael P MacManus, Andrew Wirth, Michael Michael, Kally Yuen, David L Ball

Journal article  |  2008  |  Medical Journal of Australia

Part I: Liver function in oncology: biochemistry and beyond.

Kathryn M Field, Chris Dow, Michael Michael

Journal article  |  2008  |  The Lancet Oncology

The liver has a key role in the metabolism (ie, inactivation or activation) of many commonly used anticancer agents-cytotoxics or ..

Impact of gastro-esophageal reflux on mucin mRNA expression in the esophageal mucosa.

Aafke HC van Roon, George C Mayne, Bas PL Wijnhoven, David I Watson, Mary P Leong, Gabriëlle E Neijman, Michael Z Michael, Andrew R McKay, David Astill, Damian J Hussey

Journal article  |  2008  |  Journal of Gastrointestinal Surgery

INTRODUCTION: Changes in the expression of mucin genes in the esophageal mucosa associated with uncomplicated gastro-esophageal re..

Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.

Kathryn M Field, Suzanne Kosmider, Michael Jefford, Michael Michael, Ross Jennens, Michael Green, Peter Gibbs

Journal article  |  2008  |  Journal of Oncology Practice

PURPOSE: Determining the optimal starting dose of chemotherapy (CHT) presents a considerable challenge when using body-surface are..

Locally advanced and metastatic gastric cancer - Current management and new treatment developments

Kathryn Field, Michael Michael, Trevor Leong

Journal article  |  2008  |  Drugs

Drug metabolism by tumours: its nature, relevance and therapeutic implications.

Michael Michael, Margaret M Doherty

Journal article  |  2007  |  Expert Opinion on Drug Metabolism & Toxicology

Drug-metabolising enzymes (DMEs) are present in tumours and are capable of biotransforming a variety of antineoplastics. Tumoural ..

Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.

D Goldstein, G Van Hazel, E Walpole, C Underhill, D Kotasek, M Michael, J Shapiro, T Davies, W Reece, J Harvey, N Spry

Journal article  |  2007  |  British Journal of Cancer

The aim of this phase II study was to assess the feasibility and efficacy of a specific three-dimensional conformal radiotherapy t..

Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy

Stephen Clarke, David Goldstein, Paul Mitchell, Michael Michael, Philip Beale, Michael Friedlander, John Zalcberg, Shane White

Journal article  |  2007  |  Clinical Colorectal Cancer

Tolerability of accelerated chest irradiation and impact on survival of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer: Review of a single institution's experience

Michael Ng, Jennifer Chong, Alvin Milner, Michael MacManus, Greg Wheeler, Andrew Wirth, Michael Michael, Vinod Ganju, Joe McKendrick, David Ball

Journal article  |  2007  |  Journal of Thoracic Oncology

Selective iNOS inhibition enhances spontaneous gallbladder motility in the Australian possum.

CM Woods, P Sandstrom, M Bond, M Michael, J Svanvik, J Toouli, GTP Saccone

Journal article  |  2007  |  Neurogastroenterology & Motility

Gallbladder inflammation is a common and painful disease. Inducible nitric oxide synthase (iNOS) plays a major role in inflammator..

A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer

SJ Dawson, M Michael, J Biagi, KF Foo, M Jefford, SY Ngan, T Leong, A Hui, AD Milner, RJS Thomas, JR Zalcberg

Journal article  |  2007  |  Investigational New Drugs

Prognostic factors predictive of response and survival to a modified FOLFOX regimen: Importance of an increased neutrophil count

Michael Michael, David Goldstein, Stephen J Clarke, Alvin D Milner, Phillip Beale, Michael Friedlander, Paul Mitchell

Journal article  |  2006  |  Clinical Colorectal Cancer

Relationship of hepatic functional Imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination

Michael Michael, Mick Thompson, Rod J Hicks, Paul L Mitchell, Andrew Ellis, Alvin D Milner, Julia Di Iulio, Andrew M Scott, Volker Gurtler, Janelle M Hoskins, Stephen J Clarke, Niall C Tebbut, Kian Foo, Michael Jefford, John R Zalcberg

Journal article  |  2006  |  Clinical Oncology

The caudal-related homeodomain protein Cdx2 and hepatocyte nuclear factor 1alpha cooperatively regulate the UDP-glucuronosyltransferase 2B7 gene promoter.

Philip A Gregory, Dione A Gardner-Stephen, Anne Rogers, Michael Z Michael, Peter I Mackenzie

Journal article  |  2006  |  Pharmacogenetics and Genomics

The gastrointestinal tract, contains several UDP-glucuronosyltransferases (UGTs) of the UGT1A and UGT2B subfamilies. UGT2B7 is one..

Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity

Paul L Mitchell, David Goldstein, Michael Michael, Philip Beale, Michael Friedlander, John Zalcberg, Shane White, Jacquelyn A Thomson, Stephen Clarke

Journal article  |  2006  |  Clinical Colorectal Cancer

FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer

Cuong P Duong, Rodney J Hicks, LeAnn Weih, Elizabeth Drummond, Trevor Leong, Michael Michael, Robert JS Thomas

Journal article  |  2006  |  European Journal of Nuclear Medicine and Molecular Imaging

Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.

E Ioachim, MC Michael, M Salmas, K Damala, E Tsanou, MM Michael, V Malamou-Mitsi, NE Stavropoulos

Journal article  |  2006  |  BMC Cancer

BACKGROUND: Thrombospondin-1 (TSP-1) is an extracellular matrix component glycoprotein, which is known to be a potent inhibitor of..

Recent developments in the systemic therapy of advanced gastroesophageal malignancies

K Khamly, M Jefford, M Michael, J Zalcberg

Journal article  |  2006  |  Expert Opinion on Investigational Drugs

Hypoxia-inducible factors HIF-1alpha and HIF-2alpha expression in bladder cancer and their associations with other angiogenesis-related proteins.

E Ioachim, M Michael, M Salmas, MM Michael, NE Stavropoulos, V Malamou-Mitsi

Journal article  |  2006  |  Urologia Internationalis

Hypoxia-inducible factors (HIF-1alpha and HIF-2alpha) are closely related protein complexes that activate transcription of target ..

A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC

M Michael, A Wirth, DL Ball, M MacManus, D Rischin, L Mileshkin, B Solomon, J McKendrick, AD Milner

Journal article  |  2005  |  British Journal of Cancer

Adjuvant therapy in gastric cancer

L Lim, M Michael, GB Mann, T Leong

Journal article  |  2005  |  Journal of Clinical Oncology

Gastrointestinal stromal tumour treated with neoadjuvant imatinib

MB Loughrey, C Mitchell, GB Mann, M Michael, PM Waring

Journal article  |  2005  |  Journal of Clinical Pathology

Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer

K Khamly, M Jefford, M Michael, J Zalcberg

Journal article  |  2005  |  Expert Opinion on Investigational Drugs

Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients

D Goldstein, P Mitchell, M Michael, P Beale, M Friedlander, J Zalcberg, S White, S Clarke

Journal article  |  2005  |  British Journal of Cancer

A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AN1424) to prevent chemotherapy induced peripheral neuropathy

ID Davis, L Kiers, L MacGregor, M Quinn, J Arezzo, M Green, M Rosenthal, M Chia, M Michael, P Bartley, L Harrison, M Daly

Journal article  |  2005  |  Clinical Cancer Research

Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial

S Loi, SYK Ngan, RJ Hicks, B Mukesh, P Mitchell, M Michael, J Zalcberg, T Leong, D Lim-Joon, J Mackay, D Rischin

Journal article  |  2005  |  British Journal of Cancer

Tumoral drug metabolism: overview and its implications for cancer therapy.

M Michael, MM Doherty

Journal article  |  2005  |  Journal of Clinical Oncology

Drug-metabolizing enzymes (DME) in tumors are capable of biotransforming a variety of xenobiotics, including antineoplastics, resu..

A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy

S Loi, D Rischin, M Michael, K Yuen, K Stokes, AG Ellis, MJ Millward, LK Webster

Journal article  |  2004  |  Cancer Chemotherapy and Pharmacology

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.

Michael Michael, MaryAnne Brittain, Jane Nagai, Ronald Feld, David Hedley, Amit Oza, Lillian Siu, Malcolm J Moore

Journal article  |  2004  |  Journal of Clinical Oncology

PURPOSE: The dose-limiting toxicity of irinotecan (CPT-11; Camptosar) is delayed-onset diarrhea, with an incidence at the grade 3 ..

A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer

SYK Ngan, M Michael, J Mackay, J McKendrick, T Leong, DL Joon, JR Zalcberg

Journal article  |  2004  |  British Journal of Cancer

Implications of dose rounding of chemotherapy to the nearest vial size.

Michael Joseph Dooley, Sanjay Singh, Michael Michael

Journal article  |  2004  |  Supportive Care in Cancer

GOALS OF WORK: There are practical implications of preparing cytotoxic doses calculated to the exact milligram. The objective here..

Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome

RR Jennens, MA Rosenthal, GJ Lindeman, M Michael

Journal article  |  2004  |  Urologic Oncology - Seminars and Original Investigations

A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer

M Jefford, M Michael, MA Rosenthal, ID Davis, M Green, B McClure, J Smith, B Waite, J Zalcberg

Journal article  |  2004  |  Investigational New Drugs

Impact of positron emission tomography on the management of patients with small-cell lung cancer - Preliminary experience

R Blum, MP MacManus, D Rischin, M Michael, D Ball, RJ Hicks

Journal article  |  2004  |  American Journal of Clinical Oncology - Cancer Clinical Trials

Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation

T Leong, M Michael, K Foo, A Thompson, DL Joon, L Weih, S Ngan, R Thomas, J Zalcberg

Journal article  |  2003  |  British Journal of Cancer

Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer

B Solomon, DL Ball, G Richardson, JG Smith, M Millward, M MacManus, M Michael, A Wirth, C O'Kane, L Muceniekas, G Ryan, D Rischin

Journal article  |  2003  |  Lung Cancer

A case report of oxaliplatin extravasation

KF Foo, M Michael, G Toner, J Zalcberg

Journal article  |  2003  |  Annals of Oncology

Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells.

Michael S Michael, Mostafa Z Badr, Alaa F Badawi

Journal article  |  2003  |  International journal of molecular medicine

Cyclooxygenase-2 (COX-2) expression and peroxisome proliferator-activated receptor-gamma (PPARgamma) inactivation are linked to in..

Prognostic significance of the deleted in colorectal cancer gene protein expression in high-risk resected gastric carcinoma.

Aristotle T Bamias, Maria C Bai, Niki J Agnantis, Michael C Michael, Yiannis P Alamanos, Stella V Stefanaki, Evagelia D Razi, Dimosthenis V Skarlos, Angelos M Kappas, Nicholas A Pavlidis

Journal article  |  2003  |  Cancer Investigation

The deleted in colorectal cancer (DCC) gene is a candidate tumor suppressor gene that may be associated with differentiation and p..

Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.

Fiona H Blackhall, Melania Pintilie, Michael Michael, Natasha Leighl, Ronald Feld, Ming-Sound Tsao, Frances A Shepherd

Journal article  |  2003  |  Clinical Cancer Research

PURPOSE: The Kit receptor has been proposed as a key molecular target for the treatment of small cell lung cancer (SCLC). Protein ..

Tumoral drug metabolism: perspectives and therapeutic implications.

MM Doherty, M Michael

Journal article  |  2003  |  Current Drug Metabolism

Drug metabolising enzymes (DME) in tumors are capable of biotransforming a variety of xenobiotics. Over a long period of time, man..

FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy - Survival correlates with metastatic disease burden

MP MacManus, R Hicks, R Fisher, D Rischin, M Michael, A Wirth, DL Ball

Journal article  |  2003  |  Acta Oncologica

CNS listeriosis confused with leptomeningeal carcinomatosis in a patient with a malignant insulinoma

L Mileshkin, M Michael, M O'Reilly, A McKenzie, R Stark

Journal article  |  2002  |  American Journal of Clinical Oncology

The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: Its prospective evaluation by a multicenter Canadian trial

M Michael, D Hedley, A Oza, R Feld, M Pintilie, R Goel, J Maroun, J Jolivet, A Fields, IM Lee, MJ Moore

Journal article  |  2002  |  Clinical Colorectal Cancer

Adjuvant therapy for rectal cancer

KF Foo, M Michael, J Zalcberg

Journal article  |  2002  |  Seminars in Colon [amp ] Rectal Surgery

Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer.

Alaa F Badawi, Samy L Habib, Mohammed A Mohammed, Ahmed A Abadi, Michael S Michael

Journal article  |  2002  |  Cancer Investigation

The present study examines the effect of tobacco smoking on the expression of cyclooxygenase (COX)-2 gene, COX enzymatic activity ..

Tumor markers in stage P1 bladder cancer.

NE Stavropoulos, E Ioachim, A Charchanti, MC Michael, E Kitsiou, I Mihailidis, K Hastazeris, NJ Agnantis

Journal article  |  2001  |  Anticancer Research

BACKGROUND: The infiltration of muscularis mucosa in superficial bladder cancer has been reported to be predictive of an unfavoura..

Chemotherapy for advanced colorectal cancer

MM Kirollos, D Munday, M Michael, J Zalcberg, DI Jeffrey

Journal article  |  2001  |  BMJ

Chemotherapy for advanced colorectal cancer.

M Michael, JR Zalcberg

Journal article  |  2000  |  BMJ

The optimal 5-fluorouracil regimen for the adjuvant therapy of colon cancer: Where to from here?

M Michael, JR Zalcberg

Journal article  |  2000  |  Annals of Oncology

A phase I trial of docetaxel and gemcitabine in patients with advanced cancer

D Rischin, M Boyer, J Smith, M Millward, M Michael, J Bishop, J Zalcberg, J Davison, E Emmett, B McClure

Journal article  |  2000  |  Annals of Oncology

Risk factors for hepatocellular carcinoma in Egypt: the role of hepatitis-B viral infection and schistosomiasis.

AF Badawi, MS Michael

Journal article  |  1999  |  Anticancer Research

Hepatitis-B viral (HBV) infection and schistosomiasis are among the most common causes of liver cancer (hepatocellular carcinoma; ..

Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer.

M Michael, B Babic, R Khokha, M Tsao, J Ho, M Pintilie, K Leco, D Chamberlain, FA Shepherd

Journal article  |  1999  |  Journal of Clinical Oncology

PURPOSE: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are important in tumor development and progression. ..

89th Annual Meeting of the American Association for Cancer Research, New Orleans, March 28-April 1, 1998

M Michael

Conference Proceedings  |  1998  |  Current Oncology

Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.

M Michael, MJ Moore

Journal article  |  1998  |  ONCOLOGY

In all patients with advanced colorectal cancer, disease eventually progresses following fluorouracil (5-FU) therapy, with a worse..

Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment.

M Michael, IF Tannock

Journal article  |  1998  |  CMAJ

Quality of life is a subjective multidimentional concept that can be assessed by means of validated questionnaires completed by pa..

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.

LL Siu, AM Oza, EA Eisenhauer, PS Firby, JJ Thiessen, M Michael, N Wainman, J Manzo, R Feld, RA Goldberg, MJ Moore

Journal article  |  1998  |  Journal of Clinical Oncology

PURPOSE: 9-Aminocamptothecin (9-AC) is a water-insoluble camptothecin (CMP) derivative that inhibits normal topoisomerase I functi..

Clinical experience with gemcitabine in pancreatic carcinoma.

M Michael, M Moore

Journal article  |  1997  |  ONCOLOGY

The treatment of advanced pancreatic carcinoma has been viewed with pessimism. Because of the lack of activity of commonly used ag..

Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.

M Michael, GC Toner, IN Olver, A Fenessy, JF Bishop

Journal article  |  1997  |  American Journal of Clinical Oncology

This study investigated dose intensification of epirubicin administered as a 2-weekly regimen with granulocyte-macrophage colony-s..

Australian multicentre phase II trial of paclitaxel in women with metastatic breast cancer and prior chemotherapy

M Michael, JF Bishop, JA Levi, DR Bell, JR Zalcberg, ML Friedlander, IN Olver, JG Smith, GC Toner

Journal article  |  1997  |  Medical Journal of Australia

Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.

JD Shapiro, MJ Millward, D Rischin, JD Davison, M Michael, PA Francis, V Ganju, GC Toner

Journal article  |  1997  |  Australian and New Zealand Journal of Medicine

BACKGROUND: Metastatic breast cancer is a major cause of cancer death in Australian women. Docetaxel is a new cytotoxic drug that ..

Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

JD Shapiro, MJ Millward, D Rischin, M Michael, V Walcher, PA Francis, GC Toner

Journal article  |  1996  |  Gynecologic Oncology

Thirty-eight women with epithelial ovarian cancer were treated with gemcitabine, a new antimetabolite. All had previously received..

Association of acquired Pelger-Huet anomaly with taxoid therapy.

SK Juneja, JP Matthews, R Luzinat, Y Fan, M Michael, D Rischin, MJ Millward, GC Toner

Journal article  |  1996  |  British Journal of Haematology

We describe the occurrence of acquired Pelger-Huet anomaly (APHA) in 23 patients treated with paclitaxel (13) or docetaxel (10). A..

The immunogenicity of MUC1 peptides and fusion protein.

V Apostolopoulos, GA Pietersz, PX Xing, CJ Lees, M Michael, J Bishop, IF McKenzie

Journal article  |  1995  |  Cancer Letters

Mucin 1 (MUC1) is highly expressed in breast cancer, has an ubiquitous distribution and, due to altered glycosylation, peptides wi..

Phase I study of synthetic MUC1 peptides in breast cancer

PX Xing, M Michael, V Apostolopoulos, J Prenzoska, C Marshall, J Bishop, IFC McKenzie

Journal article  |  1995  |  International Journal of Oncology